Staff View
Targeted nanomedicine platform for cancer stem cells specific therapy

Descriptive

TitleInfo
Title
Targeted nanomedicine platform for cancer stem cells specific therapy
Name (type = personal)
NamePart (type = family)
Shah
NamePart (type = given)
Vatsal V.
NamePart (type = date)
1986-
DisplayForm
Vatsal Shah
Role
RoleTerm (authority = RULIB)
author
Name (type = personal)
NamePart (type = family)
Minko
NamePart (type = given)
Tamara
DisplayForm
Tamara Minko
Affiliation
Advisory Committee
Role
RoleTerm (authority = RULIB)
chair
Name (type = personal)
NamePart (type = family)
You
NamePart (type = given)
Guofeng
DisplayForm
Guofeng You
Affiliation
Advisory Committee
Role
RoleTerm (authority = RULIB)
internal member
Name (type = personal)
NamePart (type = family)
Hatefi
NamePart (type = given)
Arash
DisplayForm
Arash Hatefi
Affiliation
Advisory Committee
Role
RoleTerm (authority = RULIB)
internal member
Name (type = personal)
NamePart (type = family)
Dayan
NamePart (type = given)
Nava
DisplayForm
Nava Dayan
Affiliation
Advisory Committee
Role
RoleTerm (authority = RULIB)
outside member
Name (type = corporate)
NamePart
Rutgers University
Role
RoleTerm (authority = RULIB)
degree grantor
Name (type = corporate)
NamePart
Graduate School - New Brunswick
Role
RoleTerm (authority = RULIB)
school
TypeOfResource
Text
Genre (authority = marcgt)
theses
OriginInfo
DateCreated (qualifier = exact)
2013
DateOther (qualifier = exact); (type = degree)
2013-01
Place
PlaceTerm (type = code)
xx
Language
LanguageTerm (authority = ISO639-2b); (type = code)
eng
Abstract (type = abstract)
Cancer is one of the most fatal diseases in the world. More than 10 million cases of cancer are reported every year. It is responsible for one in 4 deaths in the United States.The agents that are currently used for chemotherapy fail to differentiate between the cancerous and normal cells leading to numerous adverse side-effects. Owing to their toxicity, there is limitation to the amount of dose that can be administered. Due to the lack of specificity and restriction of dose, it sometimes becomes very difficult to achieve an effective concentration within the cancer affected tissues . One of the purposes of this proposal is to evaluate various drug delivery systems utilized in cancer therapy or diagnosis for genotoxicity. If a drug delivery system is found to be genotoxic, we propose to modify these genotoxic systems so as to reduce or completely eliminate their genotoxicity. We also propose to test certain raw materials used in cosmetic industry on a regular bases for genotoxicity. The other purpose of this study is to develop a dendrimer based drug delivery system that would specifically knock down CD44 in cancerous cells. Once CD44 is knocked down, we plan to treat the cancer cells specifically using a chemotherapeutic drug, Paclitaxel attached to PPi dendrimer.
Subject (authority = RUETD)
Topic
Pharmaceutical Science
Subject (authority = ETD-LCSH)
Topic
Genetic toxicology
Subject (authority = ETD-LCSH)
Topic
Cancer--Treatment--Complications
Subject (authority = ETD-LCSH)
Topic
Stem cells--Research
RelatedItem (type = host)
TitleInfo
Title
Rutgers University Electronic Theses and Dissertations
Identifier (type = RULIB)
ETD
Identifier
ETD_4459
PhysicalDescription
Form (authority = gmd)
electronic resource
InternetMediaType
application/pdf
InternetMediaType
text/xml
Extent
xx, 162 p. : ill.
Note (type = degree)
Ph.D.
Note (type = bibliography)
Includes bibliographical references
Note (type = statement of responsibility)
by Vatsal V. Shah
Subject (authority = ETD-LCSH)
Topic
Nanomedicine
Subject (authority = ETD-LCSH)
Topic
Drug delivery systems
Identifier (type = hdl)
http://hdl.rutgers.edu/1782.1/rucore10001600001.ETD.000067832
RelatedItem (type = host)
TitleInfo
Title
Graduate School - New Brunswick Electronic Theses and Dissertations
Identifier (type = local)
rucore19991600001
Location
PhysicalLocation (authority = marcorg); (displayLabel = Rutgers, The State University of New Jersey)
NjNbRU
Identifier (type = doi)
doi:10.7282/T35M64D5
Genre (authority = ExL-Esploro)
ETD doctoral
Back to the top

Rights

RightsDeclaration (ID = rulibRdec0006)
The author owns the copyright to this work.
RightsHolder (type = personal)
Name
FamilyName
Shah
GivenName
Vatsal
Role
Copyright Holder
RightsEvent
Type
Permission or license
DateTime (encoding = w3cdtf); (qualifier = exact); (point = start)
2013-01-01 17:38:44
AssociatedEntity
Name
Vatsal Shah
Role
Copyright holder
Affiliation
Rutgers University. Graduate School - New Brunswick
AssociatedObject
Type
License
Name
Author Agreement License
Detail
I hereby grant to the Rutgers University Libraries and to my school the non-exclusive right to archive, reproduce and distribute my thesis or dissertation, in whole or in part, and/or my abstract, in whole or in part, in and from an electronic format, subject to the release date subsequently stipulated in this submittal form and approved by my school. I represent and stipulate that the thesis or dissertation and its abstract are my original work, that they do not infringe or violate any rights of others, and that I make these grants as the sole owner of the rights to my thesis or dissertation and its abstract. I represent that I have obtained written permissions, when necessary, from the owner(s) of each third party copyrighted matter to be included in my thesis or dissertation and will supply copies of such upon request by my school. I acknowledge that RU ETD and my school will not distribute my thesis or dissertation or its abstract if, in their reasonable judgment, they believe all such rights have not been secured. I acknowledge that I retain ownership rights to the copyright of my work. I also retain the right to use all or part of this thesis or dissertation in future works, such as articles or books.
Copyright
Status
Copyright protected
Availability
Status
Open
Reason
Permission or license
Back to the top

Technical

RULTechMD (ID = TECHNICAL1)
ContentModel
ETD
OperatingSystem (VERSION = 5.1)
windows xp
Back to the top
Version 8.4.8
Rutgers University Libraries - Copyright ©2022